| Followers | 42 |
| Posts | 4316 |
| Boards Moderated | 0 |
| Alias Born | 07/14/2010 |
Tuesday, February 09, 2021 8:04:05 AM
They are hemorrhaging money. Have pretty much zero revenue. They still have hundreds of millions to spend of your money until phase 3 and beyond.
Operating Margin (ttm) -905.50%
Management Effectiveness
Return on Assets (ttm) -32.60%
Return on Equity (ttm) -45.61%
Revenue $5.4M
Revenue Per Share $0.30
Operating Margin (ttm) -905.50%
Management Effectiveness
Return on Assets (ttm) -32.60%
Return on Equity (ttm) -45.61%
Revenue $5.4M
Revenue Per Share $0.30
Recent KALV News
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 05/15/2026 08:24:20 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2026 08:05:39 PM
- Form SC 14D9 - Solicitation, recommendation statements • Edgar (US Regulatory) • 05/13/2026 08:45:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/13/2026 08:25:32 PM
- Form SC TO-T - Tender offer statement by Third Party • Edgar (US Regulatory) • 05/13/2026 11:22:32 AM
- Form SC TO-C - Written communication relating to an issuer or third party • Edgar (US Regulatory) • 05/05/2026 08:51:53 PM
- Form 10-KT/A - Transition reports [Rule 13a-10 or 15d-10]: [Amend] • Edgar (US Regulatory) • 04/30/2026 08:35:40 PM
- Form SC14D9C - Written communication relating to third party tender offer • Edgar (US Regulatory) • 04/29/2026 09:10:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/29/2026 12:30:47 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/20/2026 11:42:17 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/20/2026 11:41:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/20/2026 11:40:54 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/20/2026 11:40:18 PM
- KalVista Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference • Business Wire • 04/08/2026 11:00:00 AM
- KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 04/02/2026 08:01:00 PM
- KalVista Pharmaceuticals Announces Positive Interim Phase 3 Data From KONFIDENT-KID Trial of EKTERLY® (sebetralstat) for Children Aged 2-11 Years at the 2026 Global Angioedema Leadership Conference • Business Wire • 03/30/2026 11:00:00 AM
- Form 10-KT - Transition reports [Rule 13a-10 or 15d-10] • Edgar (US Regulatory) • 03/25/2026 08:35:23 PM
- KalVista posts $49.1 million in EKTERLY revenue during eight-month transition period • IH Market News • 03/25/2026 12:39:22 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 11:16:51 AM
- KalVista Pharmaceuticals Reports Eight Months Fiscal Year 2025 Financial Results and Provides Corporate Update • Business Wire • 03/25/2026 11:00:00 AM
- KalVista Pharmaceuticals to Present New EKTERLY® (sebetralstat) Data at the 2026 Global Angioedema Leadership Conference • Business Wire • 03/20/2026 11:00:00 AM
- KalVista Pharmaceuticals to Report Eight Months Fiscal Year 2025 Financial Results and Provide Corporate Update on March 25, 2026 • Business Wire • 03/18/2026 11:00:00 AM
- KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 03/04/2026 12:00:00 PM
- KalVista Pharmaceuticals Presents New Data Highlighting High Patient Satisfaction and Evolving Treatment Trends with EKTERLY® (sebetralstat) • Business Wire • 03/02/2026 12:00:00 PM
